Wide individual variations in response to drugs is a common clinical problem, and is especially evident with coumarin anticoagulant therapy (1) (2) (3) . A possible contributing factor to such variations could be the influence of another presumably unrelated drug upon the response to the coumarin anticoagulant. Reports from several laboratories (4) (5) (6) (7) indicate that barbiturates can reduce the prothrombin response to coumarin anticoagulants. This report presents initial results of studies designed to determine the manner by which barbiturates alter the response to coumarins in man, guinea pig and dog.
MATERIAL AND METHODS
Guinea pigs. Diet, method of handling guinea pigs, and blood sample collection have been reported (8) . Drugs were administered to guinea pigs intraperitoneally, barbital and acenocoumarin as aqueous solutions of their sodium salts in 0.5 to 1 ml, and chlorobutanol in 1.0 ml of peanut oil.
Dogs. Dogs were maintained on Kibbled dog food (Big Red Co.). They were given biscoumacetate (75 mg per kg) intravenously and barbital orally (50 mg per kg). Human subjects. Ambulatory, hospitalized subj ects free from known liver, kidney or gastrointestinal disease, on a regular hospital diet were studied. Their age ranged from 40 to 60 years. Heptabarbital and acenocoumarin were administered orally. Dicumarol (bishydroxycoumarin) and biscoumacetate were administered either orally or intravenously.
Chemtical methods. The procedures for the estimation of prothrombin time (9) , Dicumarol (10) , and biscoumacetate (11) have been described. Acenocoumarin was determined by the method used for biscoumacetate except that the final extraction was made into a smaller volume (2 ml) of NaOH, and optical density was meas-* Presented in part before the American Heart Association, Philadelphia, Pa., October 
RESULTS
Studies with guinea pigs. Administration of several daily doses of 140 mg per kg of sodium barbital to guinea pigs had no effect on prothrombin time (Table I) . Administration of acenocoumarin produced the expected hypo-prothrombinemia observed previously (8) . However, in animals which had received acenocoumarin after pretreatment with barbital, no appreciable hypoprothrombinemia was noted. At this dosage level of barbital the effect was consistent; with lower doses (100 mg per kg) block of acenocoumarin effect was less complete. Pretreatment with three daily doses of chlorobutanol (125 mg per kg) also antagonized the hypo-prothrombinemia induced by acenocoumarin. The average prothrombin time in the acenocoumarin-treated control group was 70 seconds (whole plasma) and 53 seconds in the chlorobutanol-and acenocoumarin-treated group. The corresponding time was 145 seconds and 84 seconds for diluted plasma. Chlorobutanol by itself had no effect on prothrombin time.
Barbital has a half-life in plasma of about 3 days in guinea pigs, and is not appreciably metabolized (12) . The half-life of acenocoumarin, as measured by the fall in plasma concentration in guinea pigs, is much shorter than that of barbital. Considerably lower levels of acenocoumarin were found in barbital-pretreated animals than in control animals (Table II) . In both groups of animals detectable amounts of acenocoumarin were absent in the plasma at the time of prothrombin estimation (24 hours after dosage). Studies in dogs. Plasma levels of biscoumacetate after a single intravenous dose of the drug were compared with levels resulting from the same dose after pretreatment of the same animals with barbital ( Figure 1 (Wi) , and the second set in a sensitive subject (M). The first bar in each set (6) , results without barbiturate; the center bar (a), pretreated with 400 mg heptabarbital 1 hour before the anticoagulant: the last bar (j), heptabarbital 5 hours after the anticoagulant.
2) pretreatment with an orally administered barbiturate (heptabarbital) followed by an orally administered coumarin; 3) an orally administered coumarin, followed by an orally administered barbiturate; 4) an intravenous dose of a coumarin only; 5) pretreatment with an orally administered barbiturate followed by an intravenously administered coumarin. Experiments on individual subjects were carried out at 2-to 3-week intervals.
Results of experiments with biscoumacetate are shown in Figure 2 and Table III; with Dicumarol  in Table IV and with acenocoumarin in Table V . marin and a decreased prothrombin response, corm-rather than before the coumarin, had a slight efpared with experiments in which the coumarin fect in some instances, and none in others. Blood was given alone, either orally or intravenously. levels of acenocoumarol were low (less than 3.5 Administration of the barbiturate 5 hours after mg per L) in all subjects without pretreatment, * Each subject was given a single oral dose of 50 mg of acenocoumarin (no pretreatment). Three weeks later each subject received an oral dose of 400 mg of heptabarbital daily for 4 days. The last dose was followed in 1 hr by a single 50 mg oral dose of acenocoumarin., and undetectable with pretreatment. There were individual differences in the response to coumarins, but these variations are well known from previous studies (2, 11) . Pretreatment with a barbiturate had no appreciable effect on plasma levels of the anticoagulant or prothrombin time response to an intravenous dose of biscoumacetate.
It was noted that after an intravenous dose of biscoumacetate the plasma level at 24 hours was 20 to 30 mg per L, whereas after oral dosage the level was less than 10 mg per L (Table III) .
Since biscoumacetate is rapidly metabolized (about 25 per cent per hour) in man, and absorption is delayed 1 to 2 hours (11), the plasma levels of the drug 4 to 5 hours after oral dosage are consistently higher than those after intravenous administration of the same dose. Yet, the data in Table III show that at 24 hours there are higher levels following intravenous dosage than after oral dosage. The readings obtained by the method of analysis employed may represent, at least in part, a metabolite of biscoumacetate rather than the drug itself. In any event, it is apparent from these data that the metabolic fate of the drug after oral administration differs from that after intravenous administration. It is therefore conceivable that the observed difference in effect of barbiturates on orally versus intravenously administered biscoumacetate in man may be a metabolic effect rather than an effect on absorption. It has previously been shown (13) that the metabolic pathway of biscoumacetate is quite different in various species.
DISCUSSION
During studies with human subjects, Avellaneda (6) noted that a variety of orally administered barbiturates (including heptabarbital) decreased the hypo-prothrombinemic response to biscoumacetate in about two-thirds of the cases studied. The mechanism of this effect was not explained. In the present study, measurements of plasma levels of the anticoagulants revealed that barbiturateinduced reduction of hypo-prothrombinemic effect was correlated with lower plasma levels of the anticoagulant in man and in other species. The effect was observed not only with biscoumacetate but also with Dicumarol and acenocoumarin. It was shown that the relative timing of dosage and the route of administration of the coumarin derivatives were important. Barbiturate pretreatment had no appreciable influence on plasma levels or hypo-prothrombinemic effect of intravenously administered coumarin anticoagulants in man. Barbiturate administered after the coumarins also had little or no effect.
These findings exclude a vitamin K-like mechanism to explain the barbiturate effect. Unlike barbiturates, vitamin K1 is effective even when given hours or days after the coumarin, and the action is independent of the route of administration of the coumarin; furthermore, Vitamin K does not affect the plasma levels of coumarin anticoagulants (14) . Barbiturates themselves do not affect coagulation (8, 15) . The barbiturates could, however, influence the physiological disposition of the coumarin. The finding that a drug can influence the disposition of another apparently unrelated drug is not unique in man (16) or experimental animals (17) .
The question arises whether barbiturates affect the absorption of coumarin anticoagulants. It is known that absorption of Dicumarol is slow and sometimes incomplete (2) , possibly because of the low aqueous solubility of the drug at the pH range of the gastrointestinal tract. However, acenocoumarin forms a sodium salt which is quite soluble at pH 7 (8) and biscoumacetate is rapidly absorbed from the small intestine ( 11) .
Do barbiturates influence the rate of metabolism of the coumarin? Such an explanation may at first be considered unlikely, since in man the effect was not observed when the coumarin was given intravenously. However, these findings in man are different from those in the guinea pig and dog. Pretreatment of guinea pigs with barbital (and also with chlorobutanol in adequate dosage) completely inhibited the hypo-prothrombinemic action of intraperitoneally administered acenocoumarin. This species difference may be related to several factors. The doses of barbiturate employed in the experiments with human subjects were small compared with those given to the guinea pigs. In the dog, pretreatment with barbiturate results in lower biscoumacetate levels after intravenous administration of the anticoagulant. Species differences in the metabolic pathway of some coumarins have been clearly demolstrated (13) . The data in man suggest differences in the metabolic pathways of oral versus intravenous biscoumacetate. It is therefore possible that, in man, barbiturate pretreatment may influence the metabolic fate (other than absorption) of orally administered biscoumacetate, even though there is no detectable effect on the fate of intravenously administered biscoumacetate.
The results obtained in guinea pigs (antagonism of acenocoumarin bv barbital and chlorobutanol) and dogs (antagonism of biscoumacetate by barbital) are similar to the earlier observations of Baumann, Field. Overman and Link (4, 5) (antagonism of Dicumarol by chlorobutanol, aminopyrine, and so forth) in rats. Several of the drugs that produce this antagonism, including barbiturates, were known to increase the biosynthesis, excretion and tissue levels of L-ascorbic acid in dogs and rats (18) . In fact, Link and co-workers studied the effect of the "vitamin C stimulators" on Dicumarol-induced hypo-prothrombinemia, because they had previously observed that L-ascorbic acid can influence and even antagonize coumarin-induced hypo-prothrombinemia (19, 20) .
Might the coumarins themselves, like the barbiturates, stimulate the enzymes responsible for counmarin metabolism? After prolonged continuous therapy with biscoumacetate, the plasma level pattern upon discontinuation is the same as that following the initial dose (3). Repeated intravenous doses of Dicumarol or biscoumacetate given to the same subject result in similar plasma level curves (2, 13) . In fact, in the same subject the half-life of a large dose of Dicumarol or biscoumacetate is longer than that of a small dose (2, 11 
